首页   ->   新闻   ->   公司新闻

公司新闻

药明康德公布2015年第三季度财报

SHANGHAI, Nov. 3, 2015 -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: WX) announces the following financial information for the third quarter ended September 30, 2015.

Third-Quarter 2015 Highlights

  • Net Revenues Increased 23.1% Year Over Year to $213.6 Million
  • GAAP Diluted Earnings Per ADS Declined 53.7% Year Over Year to $0.21
  • Non-GAAP Diluted Earnings Per ADS Attributable to WuXi Shareholders Decreased 41.8% Year Over Year to $0.31, Reflecting Exclusion of Share-Based Compensation of $0.09, Amortization of Acquired Intangible Assets of $0.02, and Deferred Tax Impact Related to Acquired Intangible Assets of ($.01)
  • Mark-to-Market Losses on Foreign-Exchange Forward Contracts of $7.3 Million and Realized Losses on Settled Foreign-Exchange Forward Contracts of $1.6 Million Resulted from RMB Depreciation Against the U.S. Dollar in the Quarter

Third-Quarter 2015 GAAP Results

Third-quarter 2015 net revenues increased 23.1% year over year to $213.6 million. Laboratory Services revenue grew 18.0%, driven by our comprehensive and integrated drug discovery and development services. Revenue growth of 19.6% in Small-Molecule Manufacturing Services resulted from strong demand in both research manufacturing and commercial manufacturing. Biologics Services revenue had strong growth of 66.1% year over year from both development and manufacturing. Revenue growth of 34.8% in New Businesses and Other related mainly to the significant revenue increase in clinical site management services in China, offset by slower than expected growth in the emerging new businesses such as genomics, China healthcare initiatives, and e-commerce.

Third-quarter 2015 GAAP gross profit increased 14.7% year over year to $75.9 million due to 23.1% revenue growth, partially offset by increased labor costs in China and investments in new businesses. Gross margin decreased year over year to 35.5% from 38.1%. Gross margin in Laboratory Services decreased year over year to 38.3% from 41.2% due to increased labor costs in China and investments in new businesses. Gross margin in Small-Molecule Manufacturing Services was unchanged at 34.9%. The increase in gross margin in Biologics Services year over year to 32.7% from 28.6% was due to efficiencies of scale. Gross margin in New Businesses and Other decreased year over year to (1.7%) from 28.3% mainly as a result of investments in genomics and bioinformatics.

Third-quarter 2015 GAAP operating income decreased 7.0% year over year to $25.8 million mainly due to investments in new businesses, including increased selling and marketing, general and administrative, and research and development expenses and transaction expenses related to the proposed privatization, partially offset by the 14.7% increase in gross profit. Operating margin declined to 12.1% from 16.0% due to these increased operating expenses.

Third-quarter 2015 GAAP net income decreased 49.8% year over year to $16.1 million mainly due to an unfavorable change of $9.4 million in mark-to-market gains and losses on foreign-exchange forward contracts (losses of $7.3 million in the third quarter of 2015 compared to gains of $2.1 million in the third quarter of 2014), an adverse change of $3.1 million in realized gains and losses on settled foreign-exchange forward contracts (losses of $1.6 million in the third quarter of 2015 compared to gains of $1.5 million in the third quarter of 2014), the 7.0% year-over-year decrease in operating income, larger equity-method investment losses from our joint ventures with PRA and MedImmune and other equity-method investments, and higher interest expense due to higher loan balances needed to support increased investment.

Third-quarter 2015 GAAP net income attributable to WuXi shareholders decreased 52.8% year over year to $15.1 million mainly due to the 49.8% year-over-year decrease in net income and net income attributable to non-controlling interests of $1.0 million in the third quarter of 2015.

Third-quarter 2015 GAAP diluted earnings per ADS attributable to WuXi shareholders decreased 53.7% year over year to $0.21 due to the 52.8% decrease in net income attributable to WuXi shareholders and a higher number of outstanding ADSs as a result of share issuances relating to the XenoBiotic Laboratories acquisition and vesting of restricted stock units. Third-quarter 2015 GAAP comprehensive income/loss attributable to WuXi shareholders was a $9.9 million loss versus income of $41.0 million in the third quarter of 2014 mainly due to the 52.8% decrease in net income and unfavorable changes in currency translation adjustments, unrealized gains and losses on available-for-sale securities, and cash flow hedges, net of tax.

Third-Quarter 2015 Non-GAAP Results

Non-GAAP financial results exclude the impact of share-based compensation expenses and the amortization of acquired intangible assets and the associated deferred tax impact.

Third-quarter 2015 non-GAAP gross profit increased 17.3% year over year to $79.6 million due to 23.1% revenue growth, partially offset by increased labor costs in China and investments in new businesses. Non-GAAP gross margin decreased year over year to 37.2% from 39.1% for the same reasons.

Third-quarter 2015 non-GAAP operating income was substantially unchanged at $33.9 million due to investments in new businesses, including increased selling and marketing, general and administrative, and research and development expenses and transaction expenses related to the proposed privatization, substantially offset by the 17.3% increase in non-GAAP gross profit. Non-GAAP operating margin decreased to 15.9% from 19.5% due to higher operating expenses.

Third-quarter 2015 non-GAAP net income decreased 38.0% year over year to $23.6 million mainly due to an unfavorable change of $9.4 million in mark-to-market gains and losses on foreign-exchange forward contracts (losses of $7.3 million in the third quarter of 2015 compared to gains of $2.1 million in the third quarter of 2014), an adverse change in realized gains and losses on settled foreign-exchange forward contracts (losses of $1.6 million in the third quarter of 2015 compared to gains of $1.5 million in the third quarter of 2014), larger equity-method investment losses from our joint ventures with PRA and MedImmune and other equity-method investments, and higher interest expense due to higher loan balances needed to support increased investment.

Third-quarter 2015 non-GAAP net income attributable to WuXi shareholders decreased 40.7% year over year to $22.6 million mainly due to the 38.0% year-over-year decrease in net income and net income attributable to noncontrolling interests of $1.0 million in the third quarter of 2015.

Third-quarter 2015 non-GAAP diluted earnings per ADS attributable to WuXi shareholders decreased 41.8% year over year to $0.31 due to the 40.7% decrease in net income attributable to WuXi shareholders and a higher number of outstanding ADSs as a result of share issuances relating to the XenoBiotic Laboratories acquisition and vesting of restricted stock units.

Third-Quarter 2015 Results Preliminary; Upcoming WuXi Extraordinary General Meeting

The third-quarter 2015 results contained in this press release are preliminary, unaudited and unreviewed and are being released ahead of the upcoming extraordinary general meeting (or "EGM") of the WuXi shareholders. The EGM is scheduled to be held on November 25, 2015 at 10:00 a.m. Shanghai time at the executive offices of the Company located at 288 Fute Zhong Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, 200131, People's Republic of China and is being convened to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger dated as of August 14, 2015 and amended on October 20, 2015, among the Company, New WuXi Life Science Limited and WuXi Merger Limited, and the transactions contemplated thereby (the "Merger Transactions"). The related transaction statement on Schedule 13E-3 and the proxy statement (the "Proxy Statement") attached as Exhibit (a)-(1) thereto were filed with the U.S. Securities and Exchange Commission (the "SEC") on October 20, 2015. Investors, shareholders and holders of American Depositary Shares of WuXi ("ADSs", each representing eight ordinary shares of WuXi) are urged to read carefully and in their entirety these materials and other materials filed with or furnished to the SEC when they become available, as they contain important information about the company, the proposed merger and related matters. The Proxy Statement was mailed to the Company's ADS holders on or about October 26, 2015 and to the Company's shareholders on or about November 2, 2015. The Special Committee of the Board, comprised of independent directors, that reviewed the transaction recommends that stockholders approve the transaction.

In light of the upcoming EGM and possible closing of the Merger Transactions shortly thereafter, WuXi does not intend to host a conference call to discuss the financial information contained in this press release, nor is the Company providing an update to its financial guidance.

 

WUXI PHARMATECH (CAYMAN) INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(in thousands of U.S. dollars, except ordinary share, ADS and par value data)

 
   

September 30,
2015

December 31,
2014

Assets:

     

Current assets:

     

Cash and cash equivalents

 

155,241

211,456

Restricted cash

 

256

793

Short-term investments

 

201,992

223,533

Accounts receivable, net

 

193,718

162,942

Amount due from related parties

 

6,912

4,397

Inventories

 

62,766

48,546

Prepaid expenses and other current assets

 

47,462

31,990

Total current assets

 

668,347

683,657

Non-current assets:

     

Goodwill

 

86,758

53,619

Property, plant and equipment, net

 

408,561

351,688

Long-term investments

 

111,060

49,037

Intangible assets, net

 

54,413

23,020

Land use rights

 

13,570

14,120

Deferred tax assets

 

6,143

1,417

Other non-current assets

 

5,304

5,068

Total non-current assets

 

685,809

497,969

Total assets

 

1,354,156

1,181,626

       

Liabilities and equity:

     

Current liabilities:

     

Short-term and current portion of long-term debt

 

75,965

199,719

Accounts payable

 

62,928

58,466

Amount due to related parties

 

636

275

Accrued expenses

 

53,540

43,454

Deferred revenue

 

39,587

27,669

Advanced subsidies

 

14,548

12,106

Other taxes payable

 

3,036

2,299

Other current liabilities

 

33,266

29,787

Total current liabilities

 

283,506

373,775

Non-current liabilities:

     

Long-term debt, excluding current portion

 

113,806

13,987

Advanced subsidies

 

2,735

2,286

Other non-current liabilities

 

25,802

13,724

Total non-current liabilities

 

142,343

29,997

Total liabilities

 

425,849

403,772

       

Equity:

     

Ordinary shares ($0.02 par value, 5,002,550,000 authorized, 561,159,373 and 568,019,232 issued and outstanding as of December 31, 2014 and September 30, 2015, respectively)

 

11,360

11,223

Additional paid-in capital

 

395,218

295,308

Retained earnings

 

467,088

415,329

Accumulated other comprehensive income

 

29,492

55,994

Equity attributable to WuXi shareholders

 

903,158

777,854

Noncontrolling interests

 

25,149

-

Total shareholders' equity

 

928,307

777,854

Total liabilities and equity

 

1,354,156

1,181,626

 

 

 


WUXI PHARMATECH (CAYMAN) INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands of U.S. dollars, except ADS data and per ADS data)

 
 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

2015

2014

%
Change

 

2015

2014

%
Change

Net revenues:

             

Laboratory services

129,357

109,597

18.0%

 

367,109

309,126

18.8%

Small-molecule manufacturing services

52,527

43,901

19.6%

 

143,969

125,311

14.9%

Biologics services

25,022

15,062

66.1%

 

57,781

35,680

61.9%

New business and other

6,736

4,998

34.8%

 

18,963

13,512

40.3%

Total net revenues

213,642

173,558

23.1%

 

587,822

483,629

21.5%

Cost of revenues:

             

Laboratory services

(79,866)

(64,462)

23.9%

 

(228,267)

(183,264)

24.6%

Small-molecule manufacturing services

(34,199)

(28,565)

19.7%

 

(92,052)

(83,691)

10.0%

Biologics services

(16,836)

(10,756)

56.5%

 

(42,941)

(25,474)

68.6%

New business and others

(6,852)

(3,585)

91.1%

 

(19,159)

(9,845)

94.6%

Total cost of revenues

(137,753)

(107,368)

28.3%

 

(382,419)

(302,274)

26.5%

Gross profit:

             

Laboratory services

49,491

45,135

9.7%

 

138,842

125,862

10.3%

Small-molecule manufacturing services

18,328

15,336

19.5%

 

51,917

41,620

24.7%

Biologics services

8,186

4,306

90.1%

 

14,840

10,206

45.4%

New business and other

(116)

1,413

NA

 

(196)

3,667

NA

Total gross profit

75,889

66,190

14.7%

 

205,403

181,355

13.3%

Operating expenses:

             

Selling and marketing expenses

(7,510)

(5,944)

26.3%

 

(21,198)

(15,485)

36.9%

General and administrative expenses

(35,531)

(26,769)

32.7%

 

(103,260)

(71,769)

43.9%

Research and development expenses

(7,027)

(5,726)

22.7%

 

(21,079)

(14,935)

41.1%

Total operating expenses

(50,068)

(38,439)

30.3%

 

(145,537)

(102,189)

42.4%

Operating income

25,821

27,751

(7.0%)

 

59,866

79,166

(24.4%)

Other income (expenses), net:

             

Loss from equity-method investments

(1,588)

(743)

113.7%

 

(3,945)

(2,386)

65.3%

Other income (expenses), net

(6,430)

8,303

NA

 

1,046

7,483

(86.0%)

Interest income (expenses), net

2,717

3,946

(31.1%)

 

8,452

12,695

(33.4%)

Total other income (expenses), net

(5,301)

11,506

NA

 

5,553

17,792

(68.8%)

Income before income taxes

20,520

39,257

(47.7%)

 

65,419

96,958

(32.5%)

Income tax expense

(4,452)

(7,257)

(38.7%)

 

(12,120)

(17,800)

(31.9%)

Net income

16,068

32,000

(49.8%)

 

53,299

79,158

(32.7%)

Less: Net income attr. to noncontrolling interests

(963)

-

NA

 

(1,539)

-

NA

Net income attributable to WuXi shareholders

15,105

32,000

(52.8%)

 

51,760

79,158

(34.6%)

Other comprehensive income:

             

Currency translation adjustments

(20,907)

7,440

NA

 

(21,654)

(3,718)

482.4%

Unrealized gains (losses) on available-for-sale securities

(756)

2,181

NA

 

(3,506)

2,106

NA

Cash flow hedge, net of tax

(3,217)

(632)

409.0%

 

(1,343)

(632)

112.5%

Other comprehensive income (loss)

(24,880)

8,989

NA

 

(26,503)

(2,244)

*

Less: Other comprehensive income (loss) attr. to noncontrolling interests

(103)

-

NA

 

(108)

-

NA

Other comprehensive income (loss) attr. to WuXi shareholders

(24,983)

8,989

NA

 

(26,611)

(2,244)

*

Comprehensive income attributable to WuXi shareholders

(9,878)

40,989

NA

 

25,149

76,914

(67.3%)

Basic net earnings per ADS

0.21

0.46

(53.7%)

 

0.73

1.12

(34.7%)

Diluted net earnings per ADS

0.21

0.45

(53.7%)

 

0.72

1.10

(34.7%)

Weighted average ADS outstanding—basic

70,974,295

69,573,192

2.0%

 

70,648,818

70,563,939

0.1%

Weighted average ADS outstanding—diluted

72,473,753

71,091,504

1.9%

 

72,196,107

72,127,058

0.1%

 

* > 1,000%

 

 

WUXI PHARMATECH (CAYMAN) INC.

RECONCILIATION OF GAAP TO NON-GAAP

(in thousands of U.S. dollars, except ADS data and per ADS data)

 
   

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

   

2015

2014

%
Change

 

2015

2014

%
Change

GAAP gross profit

 

75,889

66,190

14.7%

 

205,403

181,355

13.3%

GAAP gross margin

 

35.5%

38.1%

   

34.9%

37.5%

 

Adjustments:

               

Share-based compensation

 

2,420

1,597

51.5%

 

6,621

4,283

54.6%

Amortization of acquired intangible assets

 

1,270

48

*

 

3,876

145

*

Non-GAAP gross profit

 

79,579

67,835

17.3%

 

215,900

185,783

16.2%

Non-GAAP gross margin

 

37.2%

39.1%

   

36.7%

38.4%

 
                 

GAAP operating income

 

25,821

27,751

(7.0%)

 

59,866

79,166

(24.4%)

GAAP operating margin

 

12.1%

16.0%

   

10.2%

16.4%

 

Adjustments:

               

Share-based compensation

 

6,811

6,121

11.3%

 

21,798

16,406

32.9%

Amortization of acquired intangible assets

 

1,270

48

*

 

3,876

145

*

Non-GAAP operating income

 

33,902

33,920

(0.1%)

 

85,540

95,717

(10.6%)

Non-GAAP operating margin

 

15.9%

19.5%

   

14.6%

19.8%

 
                 

GAAP net income

 

16,068

32,000

(49.8%)

 

53,299

79,158

(32.7%)

GAAP net margin

 

7.5%

18.4%

   

9.1%

16.4%

 

Adjustments:

               

Share-based compensation

 

6,811

6,121

11.3%

 

21,798

16,406

32.9%

Amortization of acquired intangible assets

 

1,270

48

*

 

3,876

145

*

Deferred tax impact related to acquired
intangible assets

 

(500)

(17)

*

 

(1,315)

(50)

*

Non-GAAP net income

 

23,649

38,152

(38.0%)

 

77,658

95,659

(18.8%)

Non-GAAP net margin

 

11.1%

22.0%

   

13.2%

19.8%

 
                 

Less: Net income attributable to noncontrolling interests

 

(1,026)

-

NA

 

(1,677)

-

NA

Income attributable to WuXi shareholders of ADS (Non-GAAP):

               

Basic

 

22,623

38,152

(40.7%)

 

75,981

95,659

(20.6%)

Diluted

 

22,623

38,152

(40.7%)

 

75,981

95,659

(20.6%)

                 

Basic earnings per ADS (Non-GAAP) attributable to WuXi shareholders

 

0.32

0.55

(41.9%)

 

1.08

1.36

(20.7%)

Diluted earnings per ADS (Non-GAAP) attributable to WuXi shareholders

 

0.31

0.54

(41.8%)

 

1.05

1.33

(20.6%)

                 

Weighted average ADS outstanding
– basic (Non-GAAP)

 

70,974,295

69,573,192

2.0%

 

70,648,818

70,563,939

0.1%

Weighted average ADS outstanding
– diluted (Non-GAAP)

 

72,473,753

71,091,504

1.9%

 

72,196,107

72,127,058

0.1%

                 

* > 1,000%

               
                             

We have provided the above financial information on a non-GAAP basis, which excludes share-based compensation expenses and the amortization and deferred tax impact of acquired intangible assets. The non-GAAP financial measures used herein are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors benefit from referring to these non-GAAP financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods. You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies.

About WuXi PharmaTech

WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead are predictions about future events. Although we believe that our predictions are reasonable, future events are inherently uncertain, and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the proposed privatization transaction, our ability to control our costs and sustain revenue growth, to realize the anticipated benefits of our investments, to protect our clients' intellectual property, to compete effectively, and to complete the expansion of our small-molecule manufacturing facilities in Changzhou and other manufacturing facilities and potential co-development and acquisition activities. Additional information about these and other relevant risks can be found in our Annual Report on Form 20-F for the year ended December 31, 2014. The forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by law.

Use of Non-GAAP Financial Measures

We have provided the third-quarter 2014 and 2015 financial information on a non-GAAP basis, which excludes share-based compensation expenses and the amortization and deferred tax impact of acquired intangible assets. The non-GAAP financial measures used in this press release are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors benefit from referring to these non-GAAP financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods. We expect to continue to provide such non-GAAP financial measures on a quarterly basis using a consistent method. You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies.

Statement Regarding Preliminary Unaudited Financial Information

The preliminary third quarter 2015 financial information in this press release is unreviewed, unaudited and subject to adjustment. Actual results could differ, perhaps materially, following any review of our 2015 quarterly financial information. Similarly, our quarterly results are subject to adjustment in conjunction with the audit of our annual financial results by our independent auditor.

For more information, please contact:

Ronald Aldridge
LaVoieHealthScience
Tel: +1-617-374-8800 x 109
Email: ron_aldridge@wuxiapptec.com
raldridge@lavoiehealthscience.com

Daniel H. Burch
MacKenzie Partners, Inc.
Tel: 212-929-5748 (O) 516-429-2721 (M)
Email: dburch@mackenziepartners.com

back to top